Drug intelligence / Profile preview

AS-3

Development stage: Preclinical
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

AS-3 is an antisense oligonucleotide (AO) designed to target Vascular Endothelial Growth Factor (VEGF) cDNA. It functions by being complementary to VEGF cDNA base +261–+281, leading to a remarkable reduction in VEGF protein expression. This drug has been investigated for its potential to inhibit tumor growth and improve survival in experimental pancreatic cancer by targeting angiogenesis.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on AS-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS-3.

Explore the full profile